首页> 美国卫生研究院文献>British Heart Journal >Effects on ventricular arrhythmias of oral captopril and of oral mononitrate started early in acute myocardial infarction: results of a randomised placebo controlled trial.
【2h】

Effects on ventricular arrhythmias of oral captopril and of oral mononitrate started early in acute myocardial infarction: results of a randomised placebo controlled trial.

机译:急性心肌梗塞早期开始口服卡托普利和单硝酸硝酸盐对室性心律失常的影响:一项随机安慰剂对照试验的结果。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

OBJECTIVE--To assess the effects of oral vasodilator treatment on ventricular arrhythmias in acute myocardial infarction. SETTING--Coronary care units at the John Radcliffe Hospital, Oxford, and the Royal Infirmary, Edinburgh. PATIENTS--100 patients with suspected acute myocardial infarction entered the study at a mean of 13 hours from symptom onset. DESIGN OF INTERVENTION--Double blind randomisation to 4 weeks treatment with captopril (12.5 mg three times a day after a 6.25 mg test dose (n = 32)) or isosorbide mononitrate (20 mg three times a day (n = 31)) or placebo control (n = 37). OUTCOME MEASURES--Ventricular arrhythmic events assessed by 48 hours of Holter monitoring starting at the time of randomisation. RESULTS--The number of ventricular extrasystoles/hour for captopril, mononitrate, and placebo was respectively (median and range) 6 (0-162), 4 (0-38), and 10 (0-932) (2p < 0.02 mononitrate v placebo). The number of episodes of multiple extrasystoles/hour was 0.2 (0-22), 0.3 (0-4), and 0.5 (0-19); (2p < 0.02 mononitrate v placebo). Episodes of ventricular tachycardia showed a non-significant decrease in the captopril and mononitrate groups (mean (SEM) 3.2 (0.8), 2.4 (0.7), and 4.7 (1.3) for the 48 hour period). The incidence of idioventricular rhythm was also reduced in both active treatment groups (28%, 19%, and 46% (2p < 0.05 mononitrate v placebo)). CONCLUSIONS--Oral mononitrate (and perhaps also captopril) seems to reduce the incidence of ventricular arrhythmias in the early phase of acute myocardial infarction. The effects on life-threatening arrhythmias, such as ventricular fibrillation, and on death can only be assessed in a much larger trial.
机译:目的-评估口服血管扩张剂治疗对急性心肌梗死室性心律失常的影响。地点-牛津约翰·拉德克利夫医院和爱丁堡皇家医务室的基础护理室。 PATIENTS--100怀疑有急性心肌梗塞的患者在症状发作后平均13个小时进入研究。干预措施设计-卡托普利(6.25 mg试验剂量(n = 32)后,一天两次,每天三次,每次12.5 mg)或单硝酸异山梨酯(一天三次,剂量20 mg,每天三次,n = 31),双盲随机分组至4周。安慰剂对照(n = 37)。观察指标-随机分配后开始的48小时动态心电图监测评估了室性心律失常事件。结果-卡托普利,单硝酸盐和安慰剂的每小时室性收缩期数分别为(中位数和范围)6(0-162),4(0-38)和10(0-932)(2p <0.02单硝酸盐v安慰剂)。每小时多个心脏收缩期发作次数为0.2(0-22),0.3(0-4)和0.5(0-19); (2p <0.02单硝酸盐v安慰剂)。在卡托普利和单硝酸盐组中,室性心动过速发作无明显减少(在48小时内,平均值(SEM)为3.2(0.8),2.4(0.7)和4.7(1.3))。在两个活跃的治疗组中,室性心律的发生率也降低了(分别为28%,19%和46%(2p <0.05单硝酸盐v安慰剂))。结论:口服硝酸单硝酸盐(也许还有卡托普利)似乎可以减少急性心肌梗塞早期的室性心律失常的发生率。对威胁生命的心律不齐(如心室纤颤)和死亡的影响只能在更大的试验中进行评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号